• Product name
  • Description
    Rabbit polyclonal to p53
  • Host species
  • Specificity
    The antibody detects endogenous level of total p53 protein.
  • Tested applications
    Suitable for: ChIP, WB, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human p53 aa 13-17 conjugated to keyhole limpet haemocyanin.


    Database link: P04637
    (Peptide available as ab153320, ab43615, ab84768)

  • Positive control
    • ZR751 nuclear extract lysate (ab14916) can be used as a positive control in WB. MDA and JK cell extracts; HeLa cells; Human breast carcinoma tissue. Rat breast and colon tissue lysates; Rat breast and colon tissue.



Our Abpromise guarantee covers the use of ab131442 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ChIP 1/50.
WB 1/500 - 1/1000. Predicted molecular weight: 53 kDa.Can be blocked with Recombinant Human p53R2 protein (ab153320) or Recombinant Human p53 protein (ab43615) or Recombinant Human p53 protein (ab84768).
IHC-P 1/50 - 1/100.
ICC/IF 1/100 - 1/200.


  • Function
    Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
  • Tissue specificity
    Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
  • Involvement in disease
    Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
    Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
    Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
    Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
    Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
    Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
    Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.
  • Sequence similarities
    Belongs to the p53 family.
  • Domain
    The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
  • Post-translational
    Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
    Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
    Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
    May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
    Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
    Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
    Sumoylated by SUMO1.
  • Cellular localization
    Cytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.
  • Information by UniProt
  • Database links
  • Alternative names
    • Antigen NY-CO-13 antibody
    • BCC7 antibody
    • Cellular tumor antigen p53 antibody
    • FLJ92943 antibody
    • LFS1 antibody
    • Mutant tumor protein 53 antibody
    • p53 antibody
    • p53 tumor suppressor antibody
    • P53_HUMAN antibody
    • Phosphoprotein p53 antibody
    • Tp53 antibody
    • Transformation related protein 53 antibody
    • TRP53 antibody
    • Tumor protein 53 antibody
    • Tumor protein p53 antibody
    • Tumor suppressor p53 antibody
    see all


  • All lanes : Anti-p53 antibody (ab131442) at 1/500 dilution

    Lane 1 : Wild type HAP1 whole cell lysate (20 µg)
    Lane 2 : p53 knockout HAP1 whole cell lysate (20 µg)
    Lane 3 : Saos2 (20 µg)
    Lane 4 : A431 (20 µg)

    Performed under reducing conditions.

    Predicted band size: 53 kDa

     Lanes 1 - 4: Merged signal (red and green). Green - ab131442 observed at 53 kDa. Red - loading control, ab8245, observed at 37 kDa.

    Wild-type and p53 knockout samples were subjected to SDS-PAGE. ab131442 and ab8245 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.

    Other recommended antibodies to this target are ab32389 and ab26.

  • ChiP analysis of ab131442. Expression of p21

  • Immunohistochemical analysis of rat colon tissue sections with ab131442 at 1/150 dilution.The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for one night at 4oC. A goat Anti-Rabbit IgG H&L (HRP) at 1/200 was used as secondary.

  • All lanes : Anti-p53 antibody (ab131442) at 1/1000 dilution

    Lane 1 : Rat breast tissue lysate
    Lane 2 : Rat colon tissue lysate

    Lysates/proteins at 40 µg per lane.

    Predicted band size: 53 kDa

  • ab131442 staining p53 in formalin -fixed, paraffin embedded Rat C6 cells by ICC/IF (Immunocytochemistry/Immunofluorescence). Samples were incubated with primary antibody at 1/100 dilution. A goat anti-rabbit IgG H&L (1/50 dilution) was used as the secondary antibody. 


  • Immunohistochemical analysis of rat breast tissue sections with ab131442 at 1/150 dilution. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for one night at 4oC. A goat Anti-Rabbit IgG H&L (HRP) at 1/200 was used as secondary.

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded rat breast tissue with ab131442 at 1/100 dilution. A Goat Anti-Rabbit IgG H&L (CY3) at 1/50 was used as secondary. 

  • All lanes : Anti-p53 antibody (ab131442) at 1/600 dilution

    Lane 1 : Mouse Brain
    Lane 2 : Mouse Lung
    Lane 3 : HL60 Cells

    Predicted band size: 53 kDa

    Exposure time: 5 seconds
  • ChiP analysis of ab131442 in 293T cells at a dilution of 1:50.

  • All lanes : Anti-p53 antibody (ab131442) at 1/500 dilution

    Lane 1 : MDA cell extract
    Lane 2 : JK cell extract

    Predicted band size: 53 kDa
    Observed band size: 53 kDa

  • Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling p53 with ab131442 at 1/50 dilution. Right panel was preincubated with blocking peptide.

  • Immunofluorescent analysis of methanol-fixed HeLa cells staining p53 with ab131442 at 1/100 dilution.


This product has been referenced in:
  • Qin N  et al. Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity. Oncol Lett 17:958-964 (2019). Read more (PubMed: 30655854) »
  • Assareh E  et al. A cyclic peptide reproducing the a1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. Biochem J 476:645-663 (2019). Read more (PubMed: 30700502) »
See all 66 Publications for this product

Customer reviews and Q&As


Thank you for contacting us.

Apologies for the error on the product datasheet for ab80645. Reviewing our catalogue, I have found 2 products that may be of interest that are raised against p53 aa's 11-20.

ab10803 Anti-p53 antibody [DO-2] https://www.abcam.com/ab10803
Immunogen - Recombinant protein, corresponding to amino acids 10-16 of Human p53.

ab131442 Anti-p53 antibody https://www.abcam.com/ab131442
Immunogen - Synthetic peptide conjugated to KLH, derived from around amino acids 13-17 (P-L-S-Q-E) of Human p53 (NP_000537.3).

Just let me know if you have further questions.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up